[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549419":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":33,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"TG Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"BRIUMVI® Exposed Cohort",null,"Pregnant participants with MS who are exposed to any dose of BRIUMVI® at any time during pregnancy (from conception to pregnancy outcome) or before pregnancy (within 6 months of the date of conception \\[DOC\\]).",[13],"Other: No intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"BRIUMVI® Unexposed Cohort","Pregnant participants with MS who are not exposed to any dose of BRIUMVI® or other anti-CD20 monoclonal antibodies at any time during pregnancy but may be exposed to other products for the treatment of MS.",[13],[19],{"type":20,"name":21,"description":21,"armGroupLabels":22,"otherNames":10},"OTHER","No intervention",[9,15],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"BRIUMVI® Pregnancy Registry Virtual Research Coordination Center","CONTACT","1-877-411-4605","briumvipregnancyregistry@ppd.com",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"TG Therapeutics Clinical Support Team","1-877-555-8489","clinicalsupport@tgtxinc.com",[34],{"facility":25,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"RECRUITING","Wilmington","North Carolina","28401-3331","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-77.94604,34.23556,{"lat":45,"lon":44},{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100549419","a-study-evaluating-the-effect-of-briumvi-ublituximab-on-pregnancy-and-infant-outcomes-in-participants-with-multiple-sclerosis-ms-100549419",false,"NCT06433765","A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)","BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®","Inclusion Criteria:\n\n1. For exposed cohort: Participant exposed to at least 1 dose of BRIUMVI®.\n2. For unexposed cohort: Participants not exposed to BRIUMVI® at any time during the pregnancy.\n3. Diagnosis of MS.\n4. Currently or recently (within 1 year of pregnancy outcome) pregnant.\n5. Authorization from healthcare provider to provide data to registry.\n\nExclusion Criteria:\n\n1. Prior to enrollment, participant has exposure to anti-CD20 monoclonal antibodies at any time during pregnancy.\n2. Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).\n3. Exposure to known teratogens and\u002For investigational medications during pregnancy.","FEMALE","15 Years","50 Years",{"count":60,"type":61},728,"ESTIMATED","OBSERVATIONAL","The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.",[65],"Multiple Sclerosis","2026-06-17",{"date":68,"type":69},"2026-06-18","ACTUAL",{"date":71,"type":69},"2024-06-01",{"date":73,"type":61},"2035-03-31",{"name":5,"class":6},1]